{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-066558","form_type":"8-K","ticker":null,"cik":"0001403708","company_name":"Evoke Pharma Inc","filed_at":"2023-11-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.923837+00:00","generated_at":"2026-06-07T20:14:39.874408+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Evoke Pharma faces Nasdaq delisting; hearing set for March 7, 2024","bullets":["Received Nasdaq notice on Nov 21 for non-compliance with Minimum Stockholders' Equity Requirement of $2.5M.","Hearing before Nasdaq Hearings Panel scheduled for March 7, 2024; delisting action stayed pending outcome.","Company exploring options including raising capital, but no assurance of regaining compliance.","Non-compliance risk could lead to transfer to OTC markets if delisted."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-066558","json":"https://secwatch.observer/filing/0000950170-23-066558.json","markdown":"https://secwatch.observer/filing/0000950170-23-066558.md","text":"https://secwatch.observer/filing/0000950170-23-066558.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1403708/000095017023066558/0000950170-23-066558-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1403708/000095017023066558/evok-20231127.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T20:14:39.874408+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ed620e0e65e7d4d7b153ab841421241fdce2232d","claim":"Evoke Pharma Inc received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"November 21, 2023, Evoke Pharma, Inc. (the “Company”) received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that, due to the Company’s non-compliance with Nasdaq Listing Rule 5550(b)(1) (the “Minimum Stockholders’ Equity Requirement”),which requires listed companies to maintain stockholders’ equity of at least $2.5 million, the Company was subject to delisting unless it timely requested a hearing before the Nasdaq Hearings Panel (the “Hearings Panel”). On November 27, 2023, Nasdaq notified the Company that the hearing was scheduled for M","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1403708/000095017023066558/0000950170-23-066558-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"5550(b)(1)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}